Idiopathic inflammatory myopathies
Section snippets
Epidemiology
The IIM are rare sporadic disorders. The overall annual incidence of the IIM, using older diagnostic criteria, is approximately one in 100,000. Except for juvenile dermatomyositis, the IIM are diseases of the adult. They affect more women than men, except for IBM where the male-to-female ratio may be as high as 3/1. Interestingly, the age-adjusted prevalence of IBM in people over the age of 50 is 3.5/100,000, making it the most common IIM in this age group (Phillips et al., 2000). In the Mayo
Dermatomyositis
DM presents as an acute to insidious progressive, painless, proximal muscle weakness and/or a characteristic skin rash. Patients with acute disease and/or subcutaneous calcifications can have significant pain. Proximally predominant muscle weakness results in patients having difficulty using their arms while elevated over the head and being unable to get up from a deep chair or to climb stairs. This weakness pattern does not distinguish DM from many of the other myopathies. DM may result in
Inclusion body myositis
IBM is the most common myopathy after age 50. Symptom onset before age 60 occurs in 18% to 20% of patients (Lotz et al., 1989); (Badrising et al., 2005) with a frequent delay in diagnosis of five to eight years from IBM symptom onset (Lotz et al., 1989); (Badrising et al., 2000); (Lindberg et al., 1994); (Sayers et al., 1992). Men are more frequently affected than women with a ratio of 3/1.
References (75)
- et al.
Idiopathic inflammatory myopathies
Neurol. Clin.
(1997) - et al.
Polymyositis and dermatomyositis
Lancet
(2003) - et al.
Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle
J. Neurol. Sci.
(1989) - et al.
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands
Neuromuscul. Disord.
(2004) - et al.
Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life
J. Am. Acad. Dermatol.
(2006) - et al.
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy
Am. J. Med.
(1993) - et al.
Polymyositis-dermatomyositis and malignant lesions: does an association exist?
Mayo Clin. Proc.
(1986) - et al.
High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis
Semin. Arthritis Rheum.
(1998) - et al.
Progressive myopathy with up-regulation of MHC-I associated with statin therapy
Neuromuscul. Disord.
(2007) - et al.
Tacrolimus in refractory polymyositis with interstitial lung disease
Lancet
(1999)